This finding is consistent with Han et al., who demonstrated that regorafenib significantly mitigated lipopolysaccharide (LPS)-induced secretion of IL-1β and TNF-α in a mouse model of Alzheimer's disease, suggesting a regulatory effect on the inflammatory response [11]. The gene discussed is IL1B; the disease is early-onset autosomal dominant Alzheimer disease.